268 related articles for article (PubMed ID: 37165433)
1. The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva.
Ye Z; Wang S; Shan C; Zhu Q; Xue Y; Zhang K
Orphanet J Rare Dis; 2023 May; 18(1):111. PubMed ID: 37165433
[TBL] [Abstract][Full Text] [Related]
2. Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP).
Wang H; Shore EM; Pignolo RJ; Kaplan FS
Bone; 2018 Apr; 109():218-224. PubMed ID: 29170109
[TBL] [Abstract][Full Text] [Related]
3. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
[TBL] [Abstract][Full Text] [Related]
4. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).
Towler OW; Shore EM
Dev Dyn; 2022 Jan; 251(1):164-177. PubMed ID: 34133058
[TBL] [Abstract][Full Text] [Related]
5. Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology.
Collins MT
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703179
[TBL] [Abstract][Full Text] [Related]
6. Fibrodysplasia ossificans progressiva: clinical and genetic aspects.
Pignolo RJ; Shore EM; Kaplan FS
Orphanet J Rare Dis; 2011 Dec; 6():80. PubMed ID: 22133093
[TBL] [Abstract][Full Text] [Related]
7. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
[TBL] [Abstract][Full Text] [Related]
8. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
[TBL] [Abstract][Full Text] [Related]
9. Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1
Wentworth KL; Lalonde RL; Groppe JC; Brewer N; Moody T; Hansberry S; Taylor KE; Shore EM; Kaplan FS; Pignolo RJ; Yelick PC; Hsiao EC
J Bone Miner Res; 2022 Nov; 37(11):2058-2076. PubMed ID: 36153796
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice.
Lounev V; Groppe JC; Brewer N; Wentworth KL; Smith V; Xu M; Schomburg L; Bhargava P; Al Mukaddam M; Hsiao EC; Shore EM; Pignolo RJ; Kaplan FS
J Bone Miner Res; 2024 May; 39(4):382-398. PubMed ID: 38477818
[TBL] [Abstract][Full Text] [Related]
11. TGF-Beta Induces Activin A Production in Dermal Fibroblasts Derived from Patients with Fibrodysplasia Ossificans Progressiva.
de Ruiter RD; Wisse LE; Schoenmaker T; Yaqub M; Sánchez-Duffhues G; Eekhoff EMW; Micha D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768622
[TBL] [Abstract][Full Text] [Related]
12. Granting immunity to FOP and catching heterotopic ossification in the Act.
Kaplan FS; Pignolo RJ; Shore EM
Semin Cell Dev Biol; 2016 Jan; 49():30-6. PubMed ID: 26706149
[TBL] [Abstract][Full Text] [Related]
13. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva.
Towler OW; Shore EM; Kaplan FS
Bone; 2020 Jan; 130():115116. PubMed ID: 31655222
[TBL] [Abstract][Full Text] [Related]
14. Spatial patterns of heterotopic ossification in fibrodysplasia ossificans progressiva correlate with anatomic temperature gradients.
Wang H; De Cunto CL; Pignolo RJ; Kaplan FS
Bone; 2021 Aug; 149():115978. PubMed ID: 33915334
[TBL] [Abstract][Full Text] [Related]
15. Fibrodysplasia ossificans progressiva.
Kaplan FS; Le Merrer M; Glaser DL; Pignolo RJ; Goldsby RE; Kitterman JA; Groppe J; Shore EM
Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):191-205. PubMed ID: 18328989
[TBL] [Abstract][Full Text] [Related]
16. Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.
Kaplan FS; Andolina JR; Adamson PC; Teachey DT; Finklestein JZ; Ebb DH; Whitehead B; Jacobs B; Siegel DM; Keen R; Hsiao E; Pignolo RJ
Bone; 2018 Apr; 109():276-280. PubMed ID: 28736245
[TBL] [Abstract][Full Text] [Related]
17. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.
Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ
J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634
[TBL] [Abstract][Full Text] [Related]
19. Recent progress in drug development for fibrodysplasia ossificans progressiva.
Meng X; Wang H; Hao J
Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
[TBL] [Abstract][Full Text] [Related]
20. iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
Gao P; Inada Y; Hotta A; Sakurai H; Ikeya M
Stem Cell Res Ther; 2024 Mar; 15(1):83. PubMed ID: 38500216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
